Session

IBD (Posters)

IMMUNOSENESCENCE IS A FACTOR IN RESPONSE TO INFLIXIMAB THERAPY IN IBD PATIENTS OVER 65 YEARS OF AGE
IMMUNOSENESCENCE IS A FACTOR IN RESPONSE TO INFLIXIMAB THERAPY IN IBD PATIENTS OVER 65 YEARS OF AGE

IBD (Posters)  et al.

THE ANTI IL-23/IL-12 AGENT USTEKINUMAB IS AN EFFECTIVE AND SAFE INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE REFRACTORY OR INTOLERANT TO ANTI-TNF: A MULTICENTRE ITALIAN STUDY
THE ANTI IL-23/IL-12 AGENT USTEKINUMAB IS AN EFFECTIVE AND SAFE INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE REFRACTORY OR INTOLERANT TO ANTI-TNF: A MULTICENTRE ITALIAN STUDY

IBD (Posters)  et al.

DIET-INDUCED REMISSION IS NOT LINKED TO BILE ACID MODIFICATION
DIET-INDUCED REMISSION IS NOT LINKED TO BILE ACID MODIFICATION

IBD (Posters)  et al.

SACCHAROMYCES CEREVISIAE, CANDIDA ALBICANS AND ADHERENT-INVASIVE ESCHERICHIA COLI (AIEC) INTESTINAL COLONIZATION IS NOT ASSOCIATED WITH ASCA DETECTION IN CROHN´S DISEASE
SACCHAROMYCES CEREVISIAE, CANDIDA ALBICANS AND ADHERENT-INVASIVE ESCHERICHIA COLI (AIEC) INTESTINAL COLONIZATION IS NOT ASSOCIATED WITH ASCA DETECTION IN CROHN´S DISEASE

IBD (Posters)  et al.

SUCNR1 DEFICIENCY IMPAIRS INFLAMMASOME ACTIVATION AND AMELIORATES CHRONIC DSS COLITIS
SUCNR1 DEFICIENCY IMPAIRS INFLAMMASOME ACTIVATION AND AMELIORATES CHRONIC DSS COLITIS

IBD (Posters)  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)
SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)

IBD (Posters)  et al.

UTILITY OF USTEKINUMAB IN ARTICULAR PATHOLOGY ASSOCIATED WITH CROHN´S DISEASE
UTILITY OF USTEKINUMAB IN ARTICULAR PATHOLOGY ASSOCIATED WITH CROHN´S DISEASE

IBD (Posters)  et al.

PROFILING OF HUMAN CIRCULATING DENDRITIC CELLS AND MONOCYTES SUBSETS DISCRIMINATES TYPE AND MUCOSAL STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
PROFILING OF HUMAN CIRCULATING DENDRITIC CELLS AND MONOCYTES SUBSETS DISCRIMINATES TYPE AND MUCOSAL STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

SUCCINATE RECEPTOR MEDIATES LEUKOCYTE-ENDOTHELIAL CELL INTERACTIONS INDUCED BY TNF?
SUCCINATE RECEPTOR MEDIATES LEUKOCYTE-ENDOTHELIAL CELL INTERACTIONS INDUCED BY TNF?

IBD (Posters)  et al.

STUDYING THE FEATURES OF ANEMIA IN INFLAMMATORY BOWEL DISEASES AND ITS RELATIONSHIP WITH SOME MARKERS OF ENDOTHELIAL DYSFUNCTION
STUDYING THE FEATURES OF ANEMIA IN INFLAMMATORY BOWEL DISEASES AND ITS RELATIONSHIP WITH SOME MARKERS OF ENDOTHELIAL DYSFUNCTION

IBD (Posters)  et al.

THE INFLUENCE OF PREOPERATIVE MEDICATIONS IN SURGICAL COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE IN SPAIN: A MULTICENTER STUDY OF GETECCU
THE INFLUENCE OF PREOPERATIVE MEDICATIONS IN SURGICAL COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE IN SPAIN: A MULTICENTER STUDY OF GETECCU

IBD (Posters)  et al.

MACHINE LEARNING AS A DECISION-SUPPORT TOOL FOR SELECTING PATIENTS WITH CROHN'S DISEASE FOR ABDOMINOPELVIC CT IN THE EMERGENCY DEPARTMENT
MACHINE LEARNING AS A DECISION-SUPPORT TOOL FOR SELECTING PATIENTS WITH CROHN'S DISEASE FOR ABDOMINOPELVIC CT IN THE EMERGENCY DEPARTMENT

IBD (Posters)  et al.

TREATMENT PATTERNS AMONG PATIENTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE RECEIVING BIOLOGIC THERAPY IN FRANCE, GERMANY AND THE UNITED KINGDOM
TREATMENT PATTERNS AMONG PATIENTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE RECEIVING BIOLOGIC THERAPY IN FRANCE, GERMANY AND THE UNITED KINGDOM

IBD (Posters)  et al.

GUT MICROBIAL CHANGES IN RESPONSE TO VEDOLIZUMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
GUT MICROBIAL CHANGES IN RESPONSE TO VEDOLIZUMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

DIETARY INTAKE IS ASSOCIATED WITH FLARE DEVELOPMENT IN IBD PATIENTS
DIETARY INTAKE IS ASSOCIATED WITH FLARE DEVELOPMENT IN IBD PATIENTS

IBD (Posters)  et al.

IMPACT OF 8 WEEKS TOFACITINIB TREATMENT ON HISTOLOGICAL INFLAMMATION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
IMPACT OF 8 WEEKS TOFACITINIB TREATMENT ON HISTOLOGICAL INFLAMMATION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

IBD (Posters)  et al.

MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND EVALUATION OF THERAPEUTIC RESPONSE
MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND EVALUATION OF THERAPEUTIC RESPONSE

IBD (Posters)  et al.

IMPROVEMENT OF INTESTINAL ULTRASOUND PARAMETERS WITHIN 12 WEEKS AFTER TREATMENT INDUCTION IN CD AND UC PATIENTS - FIRST INTERIM ANALYSIS OF THE TRUST BEYOND STUDY
IMPROVEMENT OF INTESTINAL ULTRASOUND PARAMETERS WITHIN 12 WEEKS AFTER TREATMENT INDUCTION IN CD AND UC PATIENTS - FIRST INTERIM ANALYSIS OF THE TRUST BEYOND STUDY

IBD (Posters)  et al.

THE GUT MICROBIOME OF HEALTHY SIBLINGS OF INFLAMMATORY BOWEL DISEASE (IBD) TWINS DISPLAYS IBD SIGNATURES
THE GUT MICROBIOME OF HEALTHY SIBLINGS OF INFLAMMATORY BOWEL DISEASE (IBD) TWINS DISPLAYS IBD SIGNATURES

IBD (Posters)  et al.

MADCAM-1 ANTAGONISM WITH ONTAMALIMAB PROMOTES DRAINAGE OF LEUKOCYTES IN VITRO THROUGH THE INTESTINAL LYMPHATIC ENDOTHELIUM FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE
MADCAM-1 ANTAGONISM WITH ONTAMALIMAB PROMOTES DRAINAGE OF LEUKOCYTES IN VITRO THROUGH THE INTESTINAL LYMPHATIC ENDOTHELIUM FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

Item 81 - 100 / 279
1 2 3 4
5
6 7 8 9 10 11 12 13 14